Saturday, 1 October, 2022

Topic: Covaxin

Covaxin safe for kids, generates higher antibody response in them than adults, says Lancet paper

The results of the phase ⅔ clinical trials of the indigenous Covid vaccine have been peer-reviewed and published in the The Lancet Infectious Diseases journal.

Drug authority clears Covaxin, Corbevax for children aged 5 to 12

DGCI also allowed emergency use of Zycov-D (Zydus Cadila vaccine) for children above 12 years.

As booster uptake lags in pvt sector, officials say health system can’t be in Covid mode forever

Third Covid vaccine dose available only in pvt hospitals. Health officials say routine procedures need to be brought back on track, but govt hospitals could be brought in if needed.

WHO move to suspend Covaxin’s UN supply won’t affect trips to UK, US & over 90 nations, govt says

Bharat Biotech is believed to have assured Government of India that it will ‘quickly’ reply to WHO about ‘deficiencies found in its manufacturing’ during an inspection last month.

Covaxin to be evaluated as Covid-19 vaccine candidate in US as FDA lifts clinical hold

As many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using Covaxin.

Covaxin supplies, trial group size — why there’s a delay in Covid vaccine for younger kids

Monthly Covaxin output between 5.5-6.5 cr. Country needs at least 15 cr doses for full coverage 15-18 age group. Choice of 6 μg dose reduced manufacturing capacity, says Bharat Biotech.

ICMR received Rs 171.74 cr in royalty from sale of Covaxin till 31 Jan, govt tells Rajya Sabha

ICMR and Bharat Biotech developed Covaxin together, and MoS Health Bharati Pawar says in written reply that the research body spent Rs 35 crore on its development.

Why you won’t get Covishield, Covaxin at a chemist yet, despite full market approval

Covishield and Covaxin have been fully authorised only for use in adults, and can only be used in a ‘programmatic setting’, which means you’ll still have to register on CoWin.

DCGI grants regular market approval to Covishield, Covaxin for use in adult population

Approval was granted under New Drugs & Clinical Trials Rules, 2019 citing conditions that Bharat Biotech & SII will submit clinical trials' data & vaccines will be supplied for programmatic setting.

Covishield, Covaxin prices may drop to Rs 275/dose after getting regular market approval

Bharat Biotech's Covaxin is currently priced at Rs 1,200 per dose while SII's Covishield costs Rs 780 at private facilities. Both the vaccines are only authorised for emergency use.

On Camera


Representational image| File photo of students writing a test | Photo: Suraj Singh Bisht | ThePrint

More Dalit students going to Oxfords, Harvards. West now gets the caste divide

There are five primary factors driving an increasing number of students from marginalised communities entering the Western institutions.
A man counts Indian currency notes inside a shop in Mumbai, India | Reuters/Francis Mascarenhas

RBI tells state refiners to reduce dollar buying in spot market, contain sharp fall in rupee

RBI has ensured that $9 billion has been made available at overseas branches of some Indian banks for the country's three state-run refiners to tap, according to sources.


File photo of former Air Chief Marshal RKS Bhadauria after flying a MiG-21 of 51 Squadron at the Srinagar airbase | ANI

Famed IAF pilot Abhinandan Varthaman’s MiG-21 Squadron bows out from Srinagar today

Known as the ‘Sword Arms’, number-plating of the squadron was done Friday. It has made way for MiG-29s to be the new 'guardian of the Valley'.
Illustration by Soham Sen | ThePrint

AAP’s filling a big vacuum in Indian politics. Question is how long it can sustain without ideology

If you find admiration for AAP qualified, if not muted among many of the Modi-BJP’s critics, it is because they question it for its lack of ideological clarity. Especially on secularism.